|
 |
Last Updated: Apr 18, 2013 - 8:26:25 PM |
Latest Research
Asbestos exposure, asbestosis, and smoking combined greatly increase lung cancer risk
The chances of developing lung cancer associated with asbestos exposure, asbestosis and smoking are dramatically increased when these three risk factors are combined, and quitting smoking significantly reduces the risk of developing lung cancer after long-term asbestos exposure, according to a new study.
Apr 12, 2013 - 4:00:00 AM
|
Latest Research
Scientists map elusive 3-D structure of telomerase enzyme, key actor in cancer, aging
Like finally seeing all the gears of a watch and how they work together, researchers from UCLA and UC Berkeley have, for the first time ever, solved the puzzle of how the various components of an entire telomerase enzyme complex fit together and function in a three-dimensional structure.
Apr 11, 2013 - 4:00:00 AM
|
Latest Research
Soy-based compound may reduce tumor cell proliferation in colorectal cancer
Research on a soy-based treatment for colorectal cancer, a promising agent in ovarian cancer, and a new drug target for advanced prostate cancer was presented at the American Association for Cancer Research 2013 Annual Meeting. The meeting took place April 6-10, 2013 in Washington, DC.
Apr 11, 2013 - 4:00:00 AM
|
Latest Research
Gabriel Hortobagyi honored for mentoring minority researchers
WASHINGTON, DC -- Gabriel Hortobagyi, M.D., professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, will receive the Jane Cooke Wright Lectureship from the American Association for Cancer Research and its Minorities in Cancer Research membership group.
Apr 10, 2013 - 4:00:00 AM
|
Latest Research
American Cancer Society awards new research and training grants
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 175 national research and training grants totaling $79,073,250 for fiscal year 2013. The grants will fund investigators at 93 institutions across the United States; 164 are new grants while 11 are renewals of previous grants. The grants will go into effect July 1, 2013.
Apr 8, 2013 - 4:00:00 AM
|
Latest Research
Researchers to develop next generation immunotherapy for children with deadly solid tumors
Recently, research using adoptive T-cell immunotherapy in blood cancers have shown success, most notably in the case of a seven-year-old girl whose leukemia went into remission using altered T-cells and a disabled HIV virus. Now, two of the pediatric cancer scientists involved in the T-cell/HIV study will develop a new experimental cancer immunotherapy treatment option for children with high-risk solid tumors based on the same novel approach that uses a patient's own T-cells to attack tumor cells.
Apr 3, 2013 - 4:00:00 AM
|
Latest Research
Breakthrough cancer-killing treatment has no side-effects
Cancer painfully ends more than 500,000 lives in the United States each year, according to the Centers for Disease Control and Prevention. The scientific crusade against cancer recently achieved a victory under the leadership of University of Missouri Curators' Professor M. Frederick Hawthorne. Hawthorne's team has developed a new form of radiation therapy that successfully put cancer into remission in mice. This innovative treatment produced none of the harmful side-effects of conventional chemo and radiation cancer therapies. Clinical trials in humans could begin soon after Hawthorne secures funding.
Apr 3, 2013 - 4:00:00 AM
|
Latest Research
Rural cancer care may be closer than you think
Research from the University of Iowa suggests that cancer care is more accessible in rural areas than thought, and this increased accessibility should be considered as changes are made in the health care system under the Affordable Care Act.
Mar 26, 2013 - 4:00:00 AM
|
Latest Research
ACMG releases report on incidental findings in clinical exome and genome sequencing
The American College of Medical Genetics and Genomics (ACMG) released the widely-anticipated ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome Sequencing report at its 2013 Annual Clinical Genetics Meeting today in Phoenix. The ACMG Annual Clinical Genetics Meeting is one of the largest gatherings of medical and health professionals in genetics in the world.
Mar 21, 2013 - 4:00:00 AM
|
Latest Research
Nurses can play key role in reducing deaths from world's most common diseases
Nurses and midwives can play a critical role in lessening people's risk of cardiovascular diseases, cancers, chronic respiratory disease and diabetes, according to a groundbreaking new report issued by the World Health Organization and co-authored by a UCLA nursing professor.
Mar 19, 2013 - 4:00:00 AM
|
Latest Research
Digital rectal exam remains important part of prostate screening
The digital rectal exam is an important screening test that can discover prostate cancer that a prostate-specific antigen or PSA test may not, despite the higher sensitivity of the PSA test, according to Penn State College of Medicine researchers.
Mar 18, 2013 - 4:00:00 AM
|
Latest Research
American Academy of Microbiology releases resistance report
What do cancer cells, weeds, and pathogens have in common? They all evolve resistance to the treatments that are supposed to eliminate them. However, researchers developing the next generation of antibiotics, herbicides, and anti-cancer therapeutics rarely come together to explore the common evolutionary principles at work across their different biological systems. The new American Academy of Microbiology report Moving Targets: Fighting Resistance in Infections, Pests, and Cancer concludes that scientists working on different kinds of treatments have much to learn from each other. Applying lessons learned about the evolution of resistance in different biological systems during the earliest stages of drug and pesticide design could lead to more effective treatments for patients, farmers, and public health organizations.
Mar 7, 2013 - 5:00:00 AM
|
Latest Research
Pediatric cancer charities partner to fund international collaborative research
Solving Kids' Cancer, along with U.K.-based charities Neuroblastoma Alliance UK, J-A-C-K, and other European organizations have aligned forces to improve access to promising clinical trials for children with high-risk neuroblastoma in North America, the U.K. and Europe. The aim of the International Neuroblastoma Research Collaborative (INBRC) is to bring the cancer research community together to produce immunotherapy options to treat, control and prevent the recurrence of neuroblastoma in children. The new initiative mandates a collaboration of international cancer centers, offering a grant award of up to $500,000 (USD).
Mar 4, 2013 - 5:00:00 AM
|
Latest Research
Study confirms safety of colonoscopy
Colon cancer develops slowly. Precancerous lesions usually need many years to turn into a dangerous carcinoma. They are well detectable in an endoscopic examination of the colon called colonoscopy and can be removed during the same examination. Therefore, regular screening can prevent colon cancer much better than other types of cancer. Since 2002, colonoscopy is part of the national statutory cancer screening program in Germany for all insured persons aged 55 or older.
Mar 1, 2013 - 5:00:00 AM
|
Latest Research
Interdisciplinary education seeks to improve palliative care
LOUISVILLE, Ky. - A unique curriculum at the University of Louisville is preparing medical, nursing, social work and pastoral care students to work together on interdisciplinary teams, so patients can receive better care when facing a serious illness.
Feb 22, 2013 - 5:00:00 AM
|
Latest Research
Dr. Lewis Cantley awarded $3 million breakthrough prize in life sciences
NEW YORK (Feb. 21, 2013) -- Dr. Lewis Cantley, a leading cancer researcher credited with discovering a family of enzymes fundamental to understanding cancer, was named a winner of the inaugural Breakthrough Prize in Life Sciences, the world's richest academic prize for medicine and biology. The prize, which carries a $3 million cash award, recognizes excellence in research aimed at curing intractable diseases and human life.
Feb 21, 2013 - 5:00:00 AM
|
Latest Research
Researchers in Manchester find genetic key to preventing spine tumors
Genetic medicine experts from Manchester Biomedical Research Centre at Saint Mary's Hospital and The University of Manchester have identified a new gene responsible for causing an inherited form of tumour, known as spinal meningioma.Professor Richard Marias, Director of the Paterson Institute
Feb 18, 2013 - 5:00:00 AM
|
Latest Research
Research improving breast cancer treatment by targeting tumor initiating cells
MANHATTAN, KAN. -- A Kansas State University professor's research on breast cancer stem cells may help improve survival rates by preventing cancer recurrence and metastasis -- the major causes of death among breast cancer patients.
Feb 13, 2013 - 5:00:00 AM
|
Latest Research
UIC researchers to study how young adults use e-cigarettes, snus
Researchers at the University of Illinois at Chicago's Institute for Health Research and Policy have received a $2.3 million federal grant to study how young adults use hookahs, snus, electronic cigarettes, and other new tobacco products.
Feb 7, 2013 - 5:00:00 AM
|
Latest Research
North Shore-LIJ awarded $300,000 federal grant for prostate cancer research training
The North Shore-LIJ Health System announced today it has received a $300,000 grant from the US Department of Defense to train Hampton University undergraduates in research that will focus on the racial disparities in prostate cancer treatments, access to care and outcomes.
Feb 6, 2013 - 5:00:00 AM
|
Latest Research
$5 million awarded in Sixth Starr Cancer Consortium Grant Competition
NEW YORK (Feb. 1, 2013) -- Cancer research teams from Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College, the New York City based members of the Starr Cancer Consortium (SCC), are winners of $5 million in grant awards from The Starr Foundation's Sixth Starr Cancer Consortium Grant Competition to fund five novel cancer research projects.
Feb 1, 2013 - 5:00:00 AM
|
Latest Research
1 of the key circuits in regulating genes involved in producing blood stem cells is deciphered
Researchers from the group on stem cells and cancer at IMIM (Hospital del Mar Medical Research Institute) have deciphered one of the gene regulation circuits which would make it possible to generate hematopoietic blood cells, i.e. blood tissue stem cells. This finding is essential to generate these cells in a laboratory in the future, a therapy that could benefit patients with leukaemia or other diseases who need a transplant and who, in many cases, do not have a compatible donor.
Jan 31, 2013 - 5:00:00 AM
|
Latest Research
The potential of psilocybin to alleviate psychological distress in cancer patients is revealed
Improvements in the diagnosis and treatment of cancers in recent years have led to a marked increase in patients' physical survival rates. While doctors can treat the physical disease, what is not well understood is how best to address the psychological needs of patients with cancer.
Jan 31, 2013 - 5:00:00 AM
|
Latest Research
Gene mutation immortalizes malignant melanoma
About ten percent of all cases of malignant melanoma are familial cases. The genome of affected families tells scientists a lot about how the disease develops. Prof. Dr. Rajiv Kumar of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) together with Prof. Dr. Dirk Schadendorf from Essen University Hospital studied a family where 14 family members were affected by malignant melanoma.
Jan 25, 2013 - 5:00:00 AM
|
Latest Research
:
Cancer
:
Breast Cancer
Blood test predicts breast cancer recurrence
London, Jan 20 - A simple blood test could tell whether the commonest form of breast cancer will recur post therapy, sparing women unwanted treatment with anti-cancer drugs.
Jan 20, 2013 - 7:22:02 PM
|
Latest Research
Radiation Research Society honors 2 faculty
Two Washington University faculty members have received awards from the Radiation Research Society recognizing their contributions to research in the field and their service to the society.
Dec 19, 2012 - 5:00:00 AM
|
Latest Research
Better approach to treating deadly melanoma identified by scientists
Scientists at The University of Manchester have identified a protein that appears to hold the key to creating more effective drug treatments for melanoma, one of the deadliest cancers.
Dec 19, 2012 - 5:00:00 AM
|
Latest Research
New form of cell division found
MADISON -- Researchers at the University of Wisconsin Carbone Cancer Center have discovered a new form of cell division in human cells.
Dec 17, 2012 - 5:00:00 AM
|
Latest Research
New multiple myeloma drug shows promise in treating people with advanced disease
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
Dec 10, 2012 - 5:00:00 AM
|
Latest Research
Engineered immune cells produce complete response in child with an aggressive pediatric leukemia
By reprogramming a 7-year-old girl's own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom-designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child's doctors found that she had no evidence of cancer.
Dec 9, 2012 - 5:00:00 AM
|
Latest Research
More than a third of high-risk leukemia patients respond to an experimental new drug
A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial. In more than a third of participants, the leukemia was completely cleared from the bone marrow, and as a result, many of these patients were able to undergo potentially curative bone marrow transplants, according to investigators at the Johns Hopkins Kimmel Cancer Center and nine other academic medical centers around the world. Many of the participants who did well with the new drug, quizartinib or AC220, had failed to respond to prior therapies.
Dec 9, 2012 - 5:00:00 AM
|
Latest Research
Pre-clinical data shows Angiocidin effective against leukemia
Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.
Dec 9, 2012 - 5:00:00 AM
|
Latest Research
Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine
Early results of a trial to treat leukaemia with a WT1 DNA vaccine, has shown robust vaccine-specific antibody responses in all vaccinated patients evaluated to date.
Dec 7, 2012 - 5:00:00 AM
|
Latest Research
Grove Professor receives $1.5MM to study breast cancer therapies
For some time, researchers have known about disparities in diagnoses and outcomes among breast cancer patients based on race and age. However, they have been challenged to develop a set of criteria that can be used to reliably target drug delivery mechanisms based on an individual patient's tumor.
Nov 26, 2012 - 5:00:00 AM
|
Latest Research
Molecular 'portraits' of tumours match patients with trials in everyday clinical practice
Researchers in France are taking advantage of the progress in genetic and molecular profiling to analyse the make-up of individual cancer patients' tumours and, using this information, assign them to particular treatments and phase I clinical trials -- an approach that could become part of everyday clinical practice.
Nov 8, 2012 - 5:00:00 AM
|
Latest Research
Mesothelioma drug slows disease progression in patients with an inactive NF2 gene
Preliminary findings from the first trial of a new drug for patients with mesothelioma show that it has some success in preventing the spread of the deadly disease in patients lacking an active tumour suppressor gene called NF2. The study is presented at the 24th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Friday) [2].
Nov 8, 2012 - 5:00:00 AM
|
Latest Research
Researchers develop non-invasive technique for predicting patients' response to chemotherapy
Researchers have developed a non-invasive way of predicting how much of a cancer-killing drug is absorbed by a tumour. The preliminary study, which will be reported at the 24th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Thursday), was conducted in lung cancer patients and it also revealed that less than one per cent of the drug, docetaxel, is absorbed by the tumours [2].
Nov 7, 2012 - 5:00:00 AM
|
Latest Research
New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
A newly developed antibody targeting a signalling pathway that is frequently active in solid tumours has shown encouraging signs of efficacy in its first trial in humans, researchers will report at the 24th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Wednesday). [2]
Nov 6, 2012 - 5:00:00 AM
|
Latest Research
UCLA researchers to study depression in breast cancer survivors
UCLA researchers received a five-year, $5 million grant from the National Cancer Institute that will fund a study seeking to uncover risk profiles of breast cancer survivors likely to suffer from depression.
Nov 5, 2012 - 5:00:00 AM
|
Latest Research
Federal government renews contract for collecting and maintaining national stem cell transplantation database
The Medical College of Wisconsin (MCW) Center for International Blood and Marrow Transplant Research (CIBMTR) successfully competed for, and was awarded, renewal of the Stem Cell Therapeutics Outcomes Database contract with the U.S. Health Resources and Services Administration (HRSA). The CIBMTR administers the database as a key component of the national hematopoietic cell transplantation program. Hematopoietic stem cells are the cells responsible for continual regeneration of circulating blood cells throughout life; they are not embryonic stem cells.
Nov 1, 2012 - 4:00:00 AM
|
Latest Research
Individual gene differences can be tested in zebrafish
HERSHEY, Pa. -- The zebrafish is a potential tool for testing one class of unique individual genetic differences found in humans, and may yield information helpful for the emerging field of personalized medicine, according to a team led by Penn State College of Medicine scientists. The differences, or mutations, in question create minor changes in amino acids -- the building blocks of DNA -- from person to person. Zebrafish can be used as a model to understand what biological effects result from these genetic mutations.
Oct 25, 2012 - 4:00:00 AM
|
Latest Research
Protein levels could predict if bowel cancer patients will benefit from Avastin
Avastin, or Bevacizumab, has been shown to increase survival from bowel cancer in around ten to 15 per cent of patients, but it has been impossible to predict who will benefit.
Oct 23, 2012 - 4:00:00 AM
|
Latest Research
Penn team to explore use of brain training to help people change behaviors that increase cancer risk
PHILADELPHIA-- Most people know that smoking, a bad diet, and physical inactivity can lead to catastrophic personal health consequences, including cancer. Yet millions continue to smoke, eat poorly, and fail to get enough exercise. A new project led by researchers from the Perelman School of Medicine and the School of Arts and Sciences at the University of Pennsylvania aims to devise programs that help them change these risky behaviors and cut their risk of cancer.
Oct 22, 2012 - 4:00:00 AM
|
Latest Research
Chemistry building at Brookhaven Lab named Historic Chemical Landmark
UPTON, NY -- The New York Section of the American Chemical Society (ACS) has designated the Chemistry Building at the U.S. Department of Energy's Brookhaven National Laboratory as an Historic Chemical Landmark.* This designation honors the synthesis of 18^FDG, a radiotracer that has had a revolutionary and global impact on cancer diagnosis and management and brain research. Originally synthesized at Brookhaven Lab in 1976 for positron emission tomography (PET) scanning, 18^FDG is now the world's most widely used radiotracer for cancer diagnosis, with more than 1.5 million 18^FDG PET scans performed annually.
Oct 19, 2012 - 4:00:00 AM
|
Latest Research
Cancer Research Institute honors Dr. Laurie H. Glimcher
NEW YORK (Oct. 18, 2012) -- Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and provost for medical affairs of Cornell University, is a winner of the 2012 William B. Coley Award for Distinguished Research in Basic Immunology from the Cancer Research Institute for her outstanding achievements in immunology and cancer research.
Oct 18, 2012 - 4:00:00 AM
|
Latest Research
NIH Common Fund announces awards for Single Cell Analysis Program
The National Institutes of Health plans to invest more than $90 million over five years, contingent upon the availability of funds, to accelerate the development and application of single cell analysis across a variety of fields. The goal is to understand what makes individual cells unique and to pave the way for medical treatments that are based on disease mechanisms at the cellular level. Supported by the NIH Common Fund, NIH plans to support 26 awards as part of three initiatives of the Single Cell Analysis Program (SCAP).
Oct 15, 2012 - 4:00:00 AM
|
Latest Research
CU Cancer Center opens phase i clinical trial of anti-cancer stem cell agent OMP-54F28
The University of Colorado Cancer Center, together with other participating academic medical centers, recently opened a phase I human clinical trial of the drug OMP-54F28 in patients with advanced solid tumor cancers. OMP-54F28, a candidate investigational drug discovered by OncoMed Pharmaceuticals, targets cancer stem cells (CSCs), also known as tumor-initiating cells, which many researchers believe are at the root of tumor occurrence and growth. These CSCs are notoriously resistant to existing chemotherapies and so may survive current treatments to repopulate a tumor, leading to relapse and metastasis.
Oct 3, 2012 - 4:00:00 AM
|
Latest Research
The association of alcohol and tobacco with age at diagnosis among subjects with pancreatic cancer
Background: Pancreatic adenocarcinoma (PancCa) is a deadly disease, with essentially 100% mortality. Screening for the early detection of such cancer has not been shown to be feasible, and is currently not advised for asymptomatic people. Except for a genetic link for a small percentage of patients who have familial disease, the causes of PancCa are not known. Among environmental factors that have been implicated in some studies are smoking, heavy alcohol use, high-fat diet, excessive intake of carbonated soft drinks, obesity, chronic pancreatitis, and diabetes.Previous epidemiologic studies have had conflicting results, with some showing an increase in risk among consumers of alcohol, especially among heavy drinkers, but most showing no significant effect of moderate drinking. A monograph from IARC in 2009 concluded that there was insufficient evidence to support a role of alcohol in pancreatic cancer development.This analysis from a group of distinguished scientists supports previous research showing that smoking is associated with an earlier onset of pancreatic adenocarcinoma. Other research has shown that smoking may also be a causative factor in the development of this type of cancer.
Oct 3, 2012 - 4:00:00 AM
|
Latest Research
Genetically engineered immune system fights melanoma
MAYWOOD, Il. - Loyola University Medical Center has launched the first clinical trial in the Midwest of an experimental melanoma treatment that genetically engineers a patient's immune system to fight the deadly cancer.
Oct 1, 2012 - 4:00:00 AM
|
Latest Research
AMP appeals breast cancer gene patent case to US Supreme Court
Bethesda, MD, September 26, 2012: The Association for Molecular Pathology (AMP) has petitioned the United States Supreme Court to review the Court of Appeals for the Federal Circuit's (CAFC's) recent ruling in Association for Molecular Pathology v. U.S. Patent and Trademark Office, a case that challenges the validity of patents on two human genes, BRCA1 and BRCA2, that predispose women to hereditary breast and ovarian cancer. The American Civil Liberties Union and the Public Patent Foundation filed the appeal to the High Court on behalf of AMP and other medical and professional organizations representing over 150,000 physicians and scientists. Other plaintiffs in the suit include individual physicians and scientists, genetic counselors, women's groups and patients.
Sep 26, 2012 - 4:00:00 AM
|
|
